BioBusiness

Consulting and Venture Capital in the life science sector

[BioBusiness @BioBusiness_]

Deborah Dunsire exits as Takeda cuts CEO role in Millennium shakeup: Millennium CEO Deborah Dunsire is retirin... http://t.co/Bzppzeb9zc

[BioBusiness @BioBusiness_]

Dunsire Out At Millennium/Takeda, Replaced by Anna Protopapas: Luke Timmerman
Deborah Dunsire, the CEO w... http://t.co/IkU5PY0z7H

[BioBusiness @BioBusiness_]

Rockwell Medical Set to Disrupt Dialysis With New Drugs, DaVita Deal: Sarah Schmid
In the late 1990s, Wi... http://t.co/OtWqzqCJaE

[BioBusiness @BioBusiness_]

Dendreon Shares Fall Again, as Provenge Sales Slump: Luke Timmerman
Dendreon has made a habit of disappo... http://t.co/9OPZPDqi8S

[BioBusiness @BioBusiness_]

U.S. drug market shrinks for first time: U.S. drug spending dropped last year. While that may be welcome news ... http://t.co/fkAGKVPDWR

[BioBusiness @BioBusiness_]

The Next Billionaire: A Statistician Who Changed Medicine: Staying up-to-date has never been simpler. Sign up... http://t.co/Qsrd74bqnD

[BioBusiness @BioBusiness_]

San Diego Life Sciences Roundup: Receptos, Arena, NuVasive, & More: Bruce V. Bigelow
Amid the hectic pac... http://t.co/xIDlXKikZp

[BioBusiness @BioBusiness_]

Ensysce’s Bet: Combining Two Risky Drug Technologies That Add Up: Bernadette Tansey
At one edge of the s... http://t.co/Fh92BdhTNT

[BioBusiness @BioBusiness_]

Biotech Receptos claims $73M IPO prize to fuel oral MS contender: San Diego-based biotech Receptos has priced ... http://t.co/4AksSZqwly

[BioBusiness @BioBusiness_]

Global CRO Quintiles rakes in $947M as its hot IPO sells at top range: The global CRO Quintiles won some enthu... http://t.co/YR1S8H1ip7

[BioBusiness @BioBusiness_]

Trevena lands $430M Forest deal, $60M venture round as heart drug heads to PhIIb: http://t.co/EYzlGq5cMi

[BioBusiness @BioBusiness_]

Inviragen, Global Health Vaccine Maker, Bought by Takeda for $35M: Michael Davidson
Japanese pharmaceuti... http://t.co/w9OtRBDNCI

[BioBusiness @BioBusiness_]

Nimbus Discovery, Shire to Co-Develop Oral Rare Disease Drugs: Ben Fidler
Nimbus Discovery splashed onto... http://t.co/XUQy0CSnVm

[BioBusiness @BioBusiness_]

Big Pharma CEOs Rake in $1.57 Billion in Pay: Staying up-to-date has never been simpler. Sign up for the free... http://t.co/KbIINXCmIG

[BioBusiness @BioBusiness_]

Fast-growing Biogen Idec bursts the seams at new Cambridge HQ: When George Scangos took the helm at Biogen Ide... http://t.co/dovRp9AqNo

[BioBusiness @BioBusiness_]

The pharma spin-offs have just begun: After all, investors and shareholders responded strongly to Pfizer's ani... http://t.co/THMclWlOAm

[BioBusiness @BioBusiness_]

Genomics, Biotechnology's Oldest Next Big Thing: The economist Edward Fiedler famously said "He who lives by t... http://t.co/aSdFS7tT9h

[BioBusiness @BioBusiness_]

Startup biotech charges into PhII with $23M bankroll for rare disease drugs: A little more than a year ago the... http://t.co/MwQo8vGXLf

[BioBusiness @BioBusiness_]

Lumena Raises $23 Million to Advance Drug for Rare Liver Diseases: Bruce V. Bigelow
San Diego-based Lume... http://t.co/Ljwk9RmIIx

[BioBusiness @BioBusiness_]

Will $28M in Debt Financing Push Good Start Genetics to Big Finish?: Ben Fidler
Six years ago, Good Star... http://t.co/naIQ8Bhc2J